Actively Recruiting
Evaluating Daily Fenofibrate to Prevent Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation Over 36 Months
Led by Mayo Clinic · Updated on 2026-07-17
80
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the use of once-daily fenofibrate over 36 months to prevent recurrence of primary sclerosing cholangitis PSC after liver transplantation. PSC is a progressive liver disease with no established drug treatment and often leads to liver transplants. Recurrence of PSC after transplant is common and can cause serious complications including graft loss. This study compares fenofibrate-treated patients to a historical control group without such treatment to evaluate prevention of recurrent PSC. Participants who had liver transplantation for PSC 1 to 7 years prior and meet study criteria will receive fenofibrate 160mg daily for 36 months. During this time, serum markers related to bile acid metabolism and inflammation will be measured every 3 months. Participants will also undergo specialized gadoxetate-enhanced MRI scans at baseline, 12 months, and 36 months to assess bile duct function and early signs of disease recurrence. Throughout the study, researchers will monitor for clinically detectable recurrent PSC and analyze associations between blood markers and imaging results with disease development. The main outcome is the incidence of recurrent PSC after 36 months of fenofibrate treatment compared to controls. The trial includes periodic blood draws and MRI assessments and aims to improve understanding of biomarkers and imaging techniques for early detection. The total participation duration is 36 months of treatment with ongoing monitoring.
CONDITIONS
Brief Title
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here